Healthcare
Live Price
Offline$40.00
-0.10% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Calliditas Therapeutics AB (publ) (CALT) is a Healthcare stock with a market cap of $2.15B. The stock last traded around $40.00. Baseline metrics include revenue growth of +50.3%, EPS growth of -11.7%, a dividend yield of 0.0%. What stands out right now is revenue +50.3%, EPS -11.7%, free cash flow -42.6% with operating margin -31.9% and ROIC -25.3%. Valuation already assumes a fairly strong business story at price/sales 9.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines CALT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CALT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CALT Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CALT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$184.8M
+21047.5% YoY
FY Net Income
-$32.6M
+92.5% YoY
Free Cash Flow
-$87.2M
+71.8% YoY
Revenue Growth
+50.3%
EPS Growth
-11.7%
Gross Margin
93.6%
Net Margin
-38.6%
Income statement
SEK
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.2B | 803M | 229M | 874K | 185M |
| Gross Profit | 1.1B | 788M | 229M | 874K | 185M |
| Operating Income | -384M | -422M | -524M | -380M | -28M |
| EBITDA | -368M | -389M | -472M | -379M | -30M |
| Net Income | -466M | -412M | -510M | -437M | -33M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
SEK
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 974M | 1.2B | 956M | 996M | 754M |
| Total Assets | 1.9B | 2.0B | 1.5B | 1.5B | 845M |
| Total Liabilities | 1.6B | 1.2B | 452M | 250M | 57M |
| Shareholder Equity | 335M | 766M | 1.0B | 1.2B | 788M |
| Total Debt | 979M | 729M | 213M | 5M | 6M |
| Net Debt | 5M | -520M | -742M | -992M | -747M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
71M
+77.0% YoY
Capital Expenditures
16M
Free Cash Flow
87M
+71.8% YoY
Key ratios
Gross Margin
93.6%
Operating Margin
-31.9%
Net Margin
-38.6%
ROE
-84.7%
Debt / Equity
2.92x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.